BAAM
BCRX icon

Baker Avenue Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Baker Avenue Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-70
Closed -$496 – 486
2023
Q3 		$496 Buy
+70
New +$503 ﹤0.01% 1451
2023
Q1 		– Sell
-55
Closed -$631 – 1623
2022
Q4 		$631 Buy
+55
New +$686 ﹤0.01% 1237

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baker Avenue Asset Management's BCRX Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2023, closing a stake of 70 shares — an estimated $496 sold.

Baker Avenue Asset Management first reported a position in BCRX in Q4 2022 and held it in 2 quarters. The position peaked at $631 in Q4 2022. 235 funds tracked by Wall St. Rank hold BCRX as of Q4 2023.

  • Baker Avenue Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 70 BioCryst Pharmaceuticals shares in Q4 2023, an estimated $496.
  • Baker Avenue Asset Management first reported a position in BioCryst Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Baker Avenue Asset Management's BioCryst Pharmaceuticals position peaked at $631 in Q4 2022.
  • 235 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.